Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

Обзор

The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.

Вмешательства

• Другое No treatment given
  No treatment given

Первичные конечные точки

• Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management [Срок оценки: At the time of survey response (Day 1)]
• Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL [Срок оценки: At the time of survey response (Day 1)]
• Individual-reported change in BMI since initiation [Срок оценки: At the time of survey response (Day 1)]
• Individual-reported achievement of weight loss goal [Срок оценки: At the time of survey response (Day 1)]
• Individual-reported change in weight since initiation [Срок оценки: At the time of survey response (Day 1)]
• Individual-reported changes in daily life since initiation on injectable semaglutide [Срок оценки: At the time of survey response (Day 1)]

Вторичные конечные точки (12)

• Treatment expectation of individuals initiated on injectable semaglutide of ability to achieve weight loss goal using injectable semaglutide [Срок оценки: At the time of survey response (Day 1)]
• Expectation for length of time of treatment to desired result from date of initiation on injectable semaglutide at baseline [Срок оценки: At the time of survey response (Day 1)]
• Expectation of individuals initiated on injectable semaglutide for weight management who believe they will have greater success in achieving their weight loss with the use of injectable semaglutide [Срок оценки: At the time of survey response (Day 1)]
• Expected benefits of injectable semaglutide [Срок оценки: At the time of survey response (Day 1)]
• Satisfaction with weight loss since initiation [Срок оценки: At the time of survey response (Day 1)]
• Overall satisfaction with injectable semaglutide [Срок оценки: At the time of survey response (Day 1)]
• Individual-reported changes in perception of injectable semaglutide since initiation [Срок оценки: At the time of survey response (Day 1)]
• Attitudes of individuals related to obesity or weight related stigmatization or discrimination prior to/since/due to initiation on injectable semaglutide [Срок оценки: At the time of survey response (Day 1)]
• Attitudes of individuals initiated on injectable semaglutide for weight management related to obesity as a chronic disease [Срок оценки: At the time of survey response (Day 1)]
• Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being their responsibility [Срок оценки: At the time of survey response (Day 1)]
• Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being more likely with use of prescription medication for weight loss (AOMs) [Срок оценки: At the time of survey response (Day 1)]
• Degree of knowledge of individuals initiated on injectable semaglutide for weight management related to how prescription weight loss medications (AOMs) work in the body [Срок оценки: At the time of survey response (Day 1)]

Критерии участия

Критерии включения

• For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".

• Electronically provided consent obtained before any study-related activities can be completed.
• Age above or equal to 18 years at the time of providing informed consent.
• Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
• Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
• For an eligible participant (HCPs), all inclusion criteria must be answered "yes".

• Electronically provided consent obtained before any study-related activities can be completed.
• Practice in a participating country: Australia, Germany, UAE, and Spain.
• See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
• Treat at least 10 adult patients per month for weight management.
• Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
• Prescribe injectable semaglutide for weight management.
• Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.

Критерии исключения

• For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".

• Unwillingness or language barriers precluding adequate understanding or cooperation.
• Is currently or planning to become pregnant in next six months.
• Is taking injectable semaglutide for Type 2 diabetes management only.
• For an eligible participant (HCPs), all exclusion criteria must be answered "no".

• Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
• Unwillingness or language barriers precluding adequate understanding or cooperation.
• Only treats patients under 18 years of age.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Только случаи

Центры проведения

Германия · 1 центр

• Novo Nordisk Investigational Site — Bad Oeynhausen

Идентификаторы

NCT: NCT07154238 · NN9536-8412 · U1111-1314-6149

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗